Methods and systems for training an audio-based machine learning model to predict a health condition based on biological sounds emitted by a person. Audio data corresponding to biological sounds produced by the person is generated from a microphone. The audio data is segmented into a plurality of segments, each segment associated with a respective sound event. An audio-based machine learning model is executed on the plurality of segments. The audio-based machine learning model is configured to output, for each segment, a label of a medical condition and an associated a confidence score. The model is trained via active learning, in which a subset of the plurality of segments are selected based on their confidence score being below a threshold, and provided to a human for annotation.
An emergency medical treatment system is provided that can be used in connection with providing prehospital medical treatment to a patient. The system includes a patient data display device programmed to receive and display data associated with the patient; an environmental assessment device configured to capture visual, aural, or other ambient environmental data associated with an emergency treatment site associated with the patient; a patient monitoring device configured to be positioned on the patient and having multiple sensors programmed to collect physiological data or vitals data associated with the patient; and a patient data processing device configured with a speech-to-text module. Rules-based or machine learning based algorithm modules can be provided for generating alerts or making treatment option recommendations in connection with the patient data collected and displayed on the patient display device.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Methods of characterizing a tumor in a subject are disclosed. The methods include administering a contrast agent comprising superparamagnetic iron oxide nanoparticles (SPION) to a subject. After administering the contrast agent, a magnetic resonance imaging (MRI) system is used to obtain a set of MRI images of a section of the subject. The system quantifies R2* or other relaxation rates of voxels in the MRI images. The system then uses an auto-contouring tool and the relaxation rates to distinguish functional parenchyma from non-functional tissue in the section. The system displays the image on a display in which the functional parenchyma exhibits a visual appearance that differs from a visual appearance of the non-functional tissue.
This invention features methods and devices for ameliorating implant-induced inflammation and for reducing the risk of fibrosis. The methods and devices include a substrate coated with P-15 peptide positioned at the site of implantation.
This invention features methods and devices for ameliorating implant-induced inflammation and for reducing the risk of fibrosis. The methods and devices include a substrate coated with P-15 peptide positioned at the site of implantation.
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61L 27/00 - Materials for prostheses or for coating prostheses
8.
DEVICES AND METHODS FOR SEPARATING CELLS OR CELL FRAGMENTS
The present disclosure provides novel devices and methods for separating cells or cell fragments through fine control of a flow rate in the microchannel using a combined force of capillary and gravity without any external pumps. The disclosed devices and methods are unexpectedly effective in capturing various target cells, including rare bioparticles such as B cells, using only a small amount of blood sample.
An emergency medical treatment system is provided that can be used in connection with providing prehospital medical treatment to a patient. The system includes a patient data display device programmed to receive and display data associated with the patient; an environmental assessment device configured to capture visual, aural, or other ambient environmental data associated with an emergency treatment site associated with the patient; a patient monitoring device configured to be positioned on the patient and having multiple sensors programmed to collect physiological data or vitals data associated with the patient; and a patient data processing device configured with a speech-to-text module. Rules-based or machine learning based algorithm modules can be provided for generating alerts or making treatment option recommendations in connection with the patient data collected and displayed on the patient display device.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
11.
Methods for Determining a Level of Cell-Bound Complement Activation Product
This disclosure provides a novel method for detecting one or more cell fragment-bound complement activation products (CFB-CAPs) using a capillary flow system. The method eliminates the need for fresh, live cellular samples and detection by flow cytometric methods. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).
An emergency medical treatment system is provided that can be used in connection with providing prehospital medical treatment to a patient. The system includes a patient data display device programmed to receive and display data associated with the patient; an environmental assessment device configured to capture visual, aural, or other ambient environmental data associated with an emergency treatment site associated with the patient; a patient monitoring device configured to be positioned on the patient and having multiple sensors programmed to collect physiological data or vitals data associated with the patient; and a patient data processing device configured with a speech-to-text module. Rules-based or machine learning based algorithm modules can be provided for generating alerts or making treatment option recommendations in connection with the patient data collected and displayed on the patient display device.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
13.
FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING
This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Provided herein are fusion proteins comprising (i) interleukin 7 (IL-7) or an IL-7 variant and (ii) IL-21 or and IL-21 variant. Also provided herein are nucleic acids encoding a. fusion protein comprising (i) IL-7 or an IL-7 variant and (ii) IL-21 or and IL-21 variant, oncolytic viruses encoding a fusion protein comprising (i) IL-7 or an IL-7 variant and (ii) IL-21 or and IL-21 variant, and immune cells expressing a fission protein comprising (i) IL-7 or an IL- 7 variant and (ii) IL-21 or and IL-21 variant. Provided herein are also methods of using the compositions described herein for the treatment of cancer.
This disclosure provides a novel method for detecting one or more cell-bound complement activation products (CB-CAPs) using a capillary tube agglutination/lattice formation test. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).
University of Pittsburgh - of the Commonwealth System of Higher Education (USA)
Inventor
Fan, Yong
Zeleniak, Ann
Trucco, Massimo
Banerjee, Ipsita
Abstract
This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen-specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.
Polymer conjugates comprising a hydrophobic biodegradable polymer covalently attached to a mu opioid receptor (MOR) antagonist are described. Biodegradable covalent nanoparticles comprising the hydrophobic biodegradable polymer covalently attached to a MOR antagonist are provided as a vehicle for the sustained delivery of the MOR antagonist. The described MOR antagonist delivery system may be used to more effectively prevent or overcome the toxic effects of synthetic opioids.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present invention comprises a system and a computer-implemented method designed for measuring the visible colon surface area that has been seen from a colonoscope, and for displaying the results of the measurement. The method estimates the orientation of the camera of the colonoscope, estimates the travel distance of the scope camera from the axial vector lengths coming from or headed towards the focus of expansion point, and visualizing the percentage of the visible surface of the entire colon.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/31 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
H04N 7/18 - Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
This disclosure provides a novel method for detecting one or more cell fragment-bound complement activation products (CFB-CAPs) using a capillary flow system. The method eliminates the need for fresh, live cellular samples and detection by flow cytometric methods. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
20.
METHODS FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
This disclosure provides a novel method for detecting one or more cell fragment-bound complement activation products (CFB-CAPs) using a capillary flow system. The method eliminates the need for fresh, live cellular samples and detection by flow cytometric methods. The method as disclosed has a wide variety of applications, including diagnosing or monitoring lupus or pre-lupus and other diseases or disorders (e.g., autoimmune or inflammatory diseases or disorders).
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING
This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 211/66 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
22.
FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING
This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
23.
Hydrophilic polyarylene ether ketone polymer and methods of forming same
This patent document discloses a modified polymer having increased hydrophilicity and a method of preparing the same. A polyarylene ether ketone polymer having a plurality of repeating units, wherein one or more units of the plurality of repeating units contains a hydrophilic N-substituted imine, which is derived from a ketone in the one or more units.
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
ALLEGHENY SINGER RESEARCH INSTITUTE (USA)
Inventor
Fan, Yong
Zeleniak, Ann
Banerjee, Ipsita
Trucco, Massimo
Abstract
This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen- specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventor
Fan, Yong
Zeleniak, Ann
Trucco, Massimo
Banerjee, Ipsita
Abstract
This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen- specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.
Polymer conjugates comprising a hydrophobic biodegradable polymer covalently attached to a mu opioid receptor (MOR) antagonist are described. Biodegradable covalent nanoparticles comprising the hydrophobic biodegradable polymer covalently attached to a MOR antagonist are provided as a vehicle for the sustained delivery of the MOR antagonist. The described MOR antagonist delivery system may be used to more effectively prevent or overcome the toxic effects of synthetic opioids.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic kits for identifying biomarkers in blood samples consisting primarily of test strips, diagnostic biomarker reagents, and sample collection containers for medical purposes; Medical diagnostic reagents and assays for the analysis of body fluids; Test strips for measuring biomarkers in the blood Medical apparatus and instruments for analyzing and measuring biomarkers in the blood; Medical apparatus and instruments for analysis of body fluids; Microfluidic chips for medical diagnostic use; Diagnostic test kits for medical use consisting primarily of testing instruments, reagents, and test strips with analytes for biomarker detection; Diagnostic test kits for medical use consisting primarily of testing instruments, reagents, and microfluidic chips with analytes for biomarker detection Medical testing for diagnostic or treatment purposes
28.
Preparation and characterization of organic conductive threads as non-metallic electrodes and interconnects
The Board of Regents for Oklahoma State University (USA)
Allegheny Singer Research Institute (USA)
Inventor
Nelson, Toby Larue
Averick, Saadyah
Adhikari, Santosh
Abstract
This patent document discloses a method of fabricating an electrically conductive fiber coated with polythiophene and a carbon material. The low-cost method is amenable to modifications to suit the practical needs in various applications.
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCoating compositions based on derivatives of such polymers
D06M 23/08 - Processes in which the treating agent is applied in powder or granular form
D06M 23/10 - Processes in which the treating agent is dissolved or dispersed in organic solventsProcesses for the recovery of organic solvents thereof
H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
This document discloses an electrically conductive fiber coated with polythiophene and a carbon material. Also disclosed is an article of manufacture incorporating the conductive fiber.
C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCoating compositions based on derivatives of such polymers
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61B 5/296 - Bioelectric electrodes therefor specially adapted for particular uses for electromyography [EMG]
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
D06M 15/19 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with macromolecular compoundsSuch treatment combined with mechanical treatment with synthetic macromolecular compounds
D06M 15/233 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of hydrocarbons, or reaction products thereof, e.g. afterhalogenated or sulfochlorinated aromatic, e.g. styrene
The present invention comprises a system and a computer-implemented method designed for measuring the visible colon surface area that has been seen from a colonoscope, and for displaying the results of the measurement. The method estimates the orientation of the camera of the colonoscope, estimates the travel distance of the scope camera from the axial vector lengths coming from or headed towards the focus of expansion point, and visualizing the percentage of the visible surface of the entire colon.
A61B 1/31 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments
H04N 5/14 - Picture signal circuitry for video frequency region
Research Institute At Nationwide Children's Hospital (USA)
Inventor
Ahearn, Joseph M.
Liu, Chau-Ching
Manzi, Susan M.
Yu, C. Yung
Abstract
Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
32.
Method and system for monitoring hand hygiene compliance
A system for monitoring hygiene compliance includes multiple location tags, each configured to broadcast a unique identification number, and at least one event tag including a unique event identification tag and configured to detect an occurrence of a compliance event. The system further includes a mobile device being carried by a person that is configured to: receive the broadcast unique identification numbers from the location tags; determine a location based upon the received identification numbers; analyze the determined location against a location index to determine a compliance requirement; determine whether the person should complete a compliance event; if the person has completed a compliance event, receive the broadcast unique event identification tag and record the occurrence of the compliance event; if the person has not completed a compliance event, record a missed compliance event; and determine compliance information based upon the recorded compliance events and the recorded missed compliance events.
A47K 5/12 - Dispensers for soap for liquid or pasty soap
G08B 21/24 - Reminder alarms, e.g. anti-loss alarms
G06M 1/27 - Design features of general application for representing the result of count in the form of electric signals, e.g. by sensing markings on the counter drum
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G07C 9/28 - Individual registration on entry or exit involving the use of a pass the pass enabling tracking or indicating presence
33.
HYDROPHILIC POLYARYLENE ETHER KETONE POLYMER AND METHODS OF FORMING SAME
This patent document discloses a modified polymer having increased hydrophilicity and a method of preparing the same. A polyarylene ether ketone polymer having a plurality of repeating units, wherein one or more units of the plurality of repeating units contains a hydrophilic N-substituted imine, which is derived from a ketone in the one or more units.
C08L 79/04 - Polycondensates having nitrogen-containing heterocyclic rings in the main chainPolyhydrazidesPolyamide acids or similar polyimide precursors
THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (USA)
ALLEGHENY-SINGER RESEARCH INSTITUTE (USA)
Inventor
Nelson, Toby Larue
Averick, Saadyah
Adhikari, Santosh
Abstract
This patent document discloses a method of fabricating an electrically conductive fiber coated with polythiophene and a carbon material. The low-cost method is amenable to modifications to suit the practical needs in various applications.
H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
D06M 11/67 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides with cyanogen or compounds thereof, e.g. with cyanhydric acid, cyanic acid, isocyanic acid, thiocyanic acid, isothiocyanic acid or their salts, or with cyanamidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides with carbamic acid or its salts
D06M 11/75 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with phosgeneTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with compounds containing both carbon and sulfur, e.g. thiophosgene
D06M 23/10 - Processes in which the treating agent is dissolved or dispersed in organic solventsProcesses for the recovery of organic solvents thereof
THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (USA)
Inventor
Averick, Saadyah
Whiting, Donald, M.
Richter, Bertram
Cheng, Boyle
Nelson, Toby, Larue
Abstract
This document discloses an electrically conductive fiber coated with polythiophene and a carbon material. Also disclosed is an article of manufacture incorporating the conductive fiber.
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbon or graphiteTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with carbidesTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
Various fentanyl derivatives are described. The derivatives exhibit high binding affinity to opioid receptors, but also have decreased blood brain permeability as compared to standard fentanyl. This, the resulting derivatives can be less addictive than standard fentanyl. Methods of making such derivatives are also disclosed in this document.
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
37.
Isolation of pulmonary arterial endothelial cells from patients with pulmonary vascular disease and uses thereof
The present disclosure provides methods of obtaining, recovering and culturing pulmonary arterial endothelial cells from an individual patient subjected to a right heart catheterization in regard to diagnosis of pulmonary hypertension. These isolated pulmonary arterial endothelial cells from an individual patient may be utilized to generate cellular phenotyping profile for the cell population, allowing generation of a personalized pharmacotherapy regime to assist the clinician in treatment and prognosis of the disorder for an individual patient.
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Ahearn, Joseph M.
Liu, Chau-Ching
Manzi, Susan M.
Yu, C. Yung
Abstract
Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
Inventor
Ahearn, Joseph, M.
Liu, Chau-Ching
Manzi, Susan, M.
Yu, C., Yung
Abstract
Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.
Various fentanyl derivatives are described. The derivatives exhibit high binding affinity to opioid receptors, but also have decreased blood brain permeability as compared to standard fentanyl. This, the resulting derivatives can be less addictive than standard fentanyl. Methods of making such derivatives are also disclosed in this document.
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
41.
Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus. This document also describes methods for determining whether a patient who has been determined to exhibit pre-Lupus has progressed to exhibiting definite Lupus.
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
42.
CELL-BOUND COMPLEMENT ACTIVATION PRODUCT ASSAYS AS COMPANION DIAGNOSTICS FOR ANTIBODY-BASED DRUGS
Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
43.
Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
44.
Anti-lymphocyte autoantibodies as diagnostic biomarkers
Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated.
Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated.
Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
47.
Isolation of pulmonary arterial endothelial cells from patients with pulmonary vascular disease and uses thereof
The present disclosure provides methods of obtaining, recovering and culturing pulmonary arterial endothelial cells from an individual patient, subjected to a right heart catheterization in regard to diagnosis of pulmonary hypertension. These isolated pulmonary arterial endothelial cells from an individual patient may be utilized to generate cellular phenotyping profile for the cell population, allowing generation of a personalized pharmacotherapy regime to assist the clinician in treatment and prognosis of the disorder for an individual patient.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Sherman, David H.
Ehrlich, Garth D.
Janto, Benjamin
Williams, Robert M.
Rath, Christopher M.
Abstract
The present invention is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention also discloses polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS derived drug.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
50.
CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS AS DIAGNOSTIC BIOMARKERS FOR PRE-LUPUS
Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.
This document discloses methods diagnosing, monitoring and/or predicting the state of a disease such as an immune or inflammatory disease or disorder by detecting and measuring the level of one or more C-TM complexes in the bodily fluid of an individual. These complexes will serve as biomarkers for the diagnosis, monitoring or prediction of various inflammatory-based disease states. Detection of these C-TM complexes from an individual's bodily fluid sample is shown to be amenable through immunoassays such as described within this document.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
52.
ISOLATION OF PULMONARY ARTERIAL ENDOTHELIAL CELLS FROM PATIENTS WITH PULMONARY VASCULAR DISEASE AND USES THEREOF
The present disclosure provides methods of obtaining, recovering and culturing pulmonary arterial endothelial cells from an individual patient subjected to a right heart catheterization in regard to diagnosis of pulmonary hypertension. These isolated pulmonary arterial endothelial cells from an individual patient may be utilized to generate cellular phenotyping profile for the cell population, allowing generation of a personalized pharmacotherapy regime to assist the clinician in treatment and prognosis of the disorder for an individual patient.
A method and system for ordering and arranging a data set. The data set is initially accessed, the data set including includes a set of diagnostic test values and one or more outcomes for each of a plurality of patients. A first and second patient data set is retrieved from the data set. A first set of diagnostic test values are selected from the first patient data set, and a second set of diagnostic text values are selected from the second patient data set, The diagnostic test values are normalized and ordered, and equations are created describing the normalized and ordered test values. A processing device compares the created equations to determine a treatment plan for the first patient based upon determined, similarities to the second patient.
H03M 7/00 - Conversion of a code where information is represented by a given sequence or number of digits to a code where the same information is represented by a different sequence or number of digits
H03F 1/26 - Modifications of amplifiers to reduce influence of noise generated by amplifying elements
H04B 15/00 - Suppression or limitation of noise or interference
A method, system and device time resolved information compression. One or more detectors receive a plurality of protons, and a processing device resolves the received plurality of photons into a sample signal shown in a time domain. The processing device transforms the received plurality of photons as shown in the time domain into a frequency response shown in a frequency domain based upon a rate of detection of the plurality of photons and isolates a frequency peak position in the frequency response. The processing device further converts the frequency peak position into projection data.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
55.
METHOD AND SYSTEM FOR BIOLOGICAL INFORMATION ASSESSMENT
A method and system for biological information assessment receives uses a set of grouped historic medical test results to generate testing protocol recommendations medical test results for a new patient. Each medical test result represents a measured observation of a portion of a historic patient's body using a first medical testing modality. A score is generated for each of the historic patients based on the results. Based upon the generated scores, the historic patients are grouped into a set of groups corresponding to a range of assessment parameters. When a medical test result is received for a new patient, the medical test result is compared to the range of assessment parameters to determine which of the groups the new patient should be assigned. The new patient is assigned to the determined group and a recommendation for an additional medical testing protocol is generated.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Colorado State University Research Foundation (USA)
Inventor
Sherman, David H.
Ehrlich, Garth D.
Janto, Benjamin
Williams, Robert M.
Rath, Christopher M.
Abstract
The present invention is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention also discloses polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS derived drug.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07K 1/00 - General processes for the preparation of peptides
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
C12N 15/52 - Genes encoding for enzymes or proenzymes
A fluid treatment system includes a fluid source, at least one anaerobic reactor vessel and at least one aerobic reactor vessel. The anaerobic reactor vessel contains retaining a set of retaining structures that are at least partially coated with an anaerobic biofilm. The aerobic reactor vessel contains an aerobic biofilm. When fluid from the fluid source is exposed to the anaerobic biofilm, the anaerobic biofilm removes one or more metal substances from the fluid. When the fluid is exposed to the aerobic biofilm, the aerobic biofilm may cause organic materials in the fluid to metabolize. The system also may include a precipitation reactor that separates divalent metals from the fluid, a settling facility that forms a slurry comprising separated metals, and a neutralization, reactor that modifies the fluid to a substantially neutral pH.
A process and a system for assisting a clinician in identification and evaluation of perfusion characteristics of an organ are disclosed. The process and system may be used to extend clinical diagnosis capabilities by augmenting the ability to analyze perfusion images acquired from a radiology imaging modality through the use of the quantification technology as described. Classification of perfusion characteristics of a region of interest is facilitated through the use of a quantitative spatial perfusion characteristics map. The map is generated by a computing device which applies at least one physics-based image processing technique. This map is displayed on a clinician device for review by the clinician to assist in the spatial identification of perfusion abnormalities.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
A surgical drain device is disclosed. The surgical drain device may have a drainage tube, a flexible tube, a securing device and at least one connection element integrated with a portion of the flexible tube, wherein the connection element is configured and arranged to receive and immobilize the securing device in a selected position.
Embodiments herein are directed to an anchor and an insertion tool. The anchor may be sized for near cortex anchor fixation or for fixation into the intramedullary canal of a bone. Embodiments also describe a cortical anchor and insertion tool assembly including an anchor having a tool receptor, a leading face, a central face, a rear face, and a suture spool to receive suture that is situated away from a center of a longitudinal axis of the anchor; and an insertion tool having a rod member having a distal end. A tip of the rod member may include a pivot structure capable of actively pivoting the anchor at the tool receptor. In some embodiments, the anchor may be guided into a hole in a bone by the insertion tool and pivoted at the tool receptor to fully or partially cover the hole.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
A method for improved, automated analysis of a data set improves the reliability of the data set by comparing the data set with a model of similar data. The method may be used in applications such as medical imaging, clinical trial participant selection, marketing, security, traffic control, and other applications.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
64.
METHOD AND SYSTEM FOR RECOMMENDING A DECISION BASED ON COMBINED ENTITY MODELING
A method for improved, automated analysis of a data set improves the reliability of the data set by comparing the data set with a model of similar data. The method may be used in applications such as medical imaging, clinical trial participant selection, marketing, security, traffic control, and other applications.
A hand hygiene compliance monitoring system includes a portable data reader having a display and a memory, a portal trigger configured to recognize an entrance event in response to a person with the reader entering a room, and a dispenser trigger configured to cause the reader to record a dispensing event in the memory when the person with the reader causes a cleaning dispenser to dispense cleanser. The display shows feedback relating to the person's compliance with hand hygiene requirements.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Sherman, David, H.
Ehrlich, Garth, D.
Janto, Benjamin
Williams, Robert, M.
Rath, Christopher, M.
Abstract
The present invention is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention also discloses polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS derived drug.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
71.
TARGETED ACQUISITION USING HOLISTIC ORDERING (TACHO) APPROACH FOR HIGH SIGNAL TO NOISE IMAGING
An MRI includes imaging and receiving coils and a controller in communication with the coils which controls the coils to sample k space associated with a patient in a pattern based on knowledge of k-space data and reconstructs an image of the patient from the sampled k-space. The MRI acquires preliminary k-space data of a patient indicating the extent of k-space data for all receiver channels using the coils. The controller determines signal regions associated with the k-space that multiple acquisition blades will target with the coils based on the preliminary k-space. The MRI samples each region with the blades to obtain k-space data and stores the k-space data. The controller interpolates the k-space data to fit in a regular rectangular grid fits each separate blade of k-space data to the grid and averages overlapping k-space data. The MRI reconstructs an image from the k-space data.
An apparatus for diagnosing a patient includes a catheter having a tip. The apparatus includes a bioptome disposed in proximity to the tip to obtain a tissue sample of the patient. The apparatus includes a radiodetector disposed in proximity to the tip to detect radiation in the patient. A method for diagnosing a patient includes the steps of moving a tip of a catheter to a desired location in a blood vessel of the patient determined by radiation detected by a radiodetector disposed in proximity to the tip. There is the step of obtaining a tissue sample of the patient with a bioptome disposed in proximity to the tip.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
A61B 17/00 - Surgical instruments, devices or methods
Methods for identifying bacterial strains by using sets of distributed genes that are present in some but not all strains of a given species, associated methods for treating bacterial infections are disclosed. The methods may include examining a sample of a bacterial species, selecting a strain of interest based on possession of a unique genetic characteristic that is present in only the strain of interest and not in the other strains, examining the distributed genes possessed by the strain of interest, and detecting gene-possession variation in the distributed genes of the sample strains as compared to genes of known strains.
G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A method of in situ treatment of fracture fluid that is contaminated with a heavy metal may include passing a flow of contaminated fracture fluid through a reactor vessel. The reactor vessel may contain a plurality of biofilm retaining structures. Each of the structures may at least be partially coated with a biofilm. Additionally, the biofilm may include a plurality of bacteria retained in a matrix and the matrix may include DNA, protein and carbohydrates produced by the bacteria.
Apparatus and method for treating wastewater contaminated with a heavy metal (cadmium, iron, nickel, radium, uranium, cobalt, lead, manganese, arsenic ) in a reactor vessel containing a plurality of biofilm retaining structures. Each of the structures is at least partially coated with a biofilm which may include a plurality of bacteria ( Deinococcus geothermalis, Deinococcus radiodurans, Vibrio proteolyticus, Shewanella piezotolerans, Shewanella baltica, Pantoea agglomerans, Vibrio vulnificus ) retained in a matrix whereby the matrix may include DNA, protein and carbohydrates produced by the bacteria. The matrix comprises a negatively changed material that attracts positive metal ions of the metal and draws the metal into the matrix.
A method of prevention of acid rock drainage excludes oxygen from waste rocks that contain ferrous sulfides by building an oxygen bio-barrier over exposed surfaces of the waste rock. The bio-barrier may be formed by applying a slurry to the rock. The slurry may contain several components such as microbial material, one or more nutrients, water or another fluid, and optionally water-absorbent material. The microbial material may include bacteria, algae, fungi or a combination thereof. Additionally, the slurry may contain one or more acid-neutralizing compounds, one or more cellulose-containing substances, and one or more UV protecting agents.
An MRI includes imaging coils. The MRI includes receiving coils. The MRI includes a controller causing the imaging coils to produce RF pulses at every repetition time so different parts of a patient are receiving excitation by RF pulses at different rates and k space data are acquired at each repetition time by the receiving coils to form images of the patient with the k space data. A method for an MRI includes the steps of causing with a controller imaging coils to produce RF pulses at every repetition time so different parts of a patient are receiving excitation by RF pulses at different rates. There is the step of acquiring k space data at each repetition time by receiving coils. There is the step of forming images of the patient with the k space data using approaches such as Fourier transformation or filtered back projection.
An MRI includes a cylindrical housing having a long axis in which a patient is positioned essentially in parallel with the long axis of the cylindrical housing. The MRI includes an electromagnetic receiver coil system positioned about a cylindrical housing and aligned with the long axis of the cylindrical housing. The MRI includes an electromagnetic imaging gradients coil system positioned about the cylindrical housing and aligned with the long axis of the cylindrical housing. The MRI includes a main magnet having its north pole and south pole positioned about the housing, which produces a magnetic field through the housing perpendicular to the long axis of the cylindrical housing. A method for examining a patient.
A magnetic resonance imager for forming images of a moving portion of a patient includes imaging coils. The imager includes a computer that causes the imaging coils to apply continuously steady-state free precession to k-space of a magnetic resonance image series of the patient and acquire the image series, and generates images from the image series. A method for forming images of a moving portion of a patient includes the steps of applying continuously steady-state free precession to k-space of a magnetic resonance image series of a patient. There is the step of acquiring the image series. There is the step of generating images from the image series. A method for forming images of a patient includes the steps of triggering a steady-state free precision imaging sequence to an ECG r wave of cardiac cycles of the patient. There is the step of performing the steady-state free precision imaging sequence with imaging coils of a magnetic resonance imaging scanner such that data for a series of k-space data sets associated with the imaging sequence are acquired in a manner that is time resolved through the cardiac cycle, with data acquired over a number of consecutive cardiac cycles. A computer program embodied on a computer readable medium to form an image of a patient with an MRI.
An MRI to form an image of a patient includes at least one emitting coil which produces RF pulses and gradients. The MRI includes a controller in communication with the emitting coil for obtaining a steady-state image of the patient, where gradient areas balance to zero for each time repetition (TR) interval, and for causing the emitting coil to produce the RF pulses without interruption during the time repetition interval. The MRI includes at least one receiving coil in communication with the controller which receives the RF pulses and provides the RF pulses to the controller for the controller to obtain the image. A method to form an image of a patient with an MRI. A computer program embodied on a computer readable medium to form an image of a patient with an MRI.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
A method for preparing a biofilm includes the steps of rinsing the biofilm. There is the step of staining the biofilm with potassium permanganate and water.
A method of making a bioplastic, and a bioplastic produced thereby, by using human plasma in which human plasma is clotted, either dried through its gel phase or dried and powdered, and processed into a bioplastic with the addition of at least one plasticizer followed by forming and heating to form a final bioplastic construct.
A system which allows healthcare providers to monitor hand hygiene compliance includes a data reader adapted to be worn by a healthcare provider. The system includes a portal trigger disposed at each door portal of a patient room which activates the reader to record an entrance event when the provider enters the patient room. The system includes a dispenser trigger disposed at each cleaning dispenser having cleanser in or at the entrance of each patient room which activates the reader to record a dispensing event when the provider causes the dispenser to dispense cleanser, the reader having a display which displays a number of dispensing events and a number of entrance events. A method which allows healthcare providers to monitor hand hygiene compliance. A system which allows a person to monitor hand hygiene compliance. A method for allowing a person to monitor hand hygiene compliance.
A system which allows healthcare providers to monitor hand hygiene compliance includes a data reader adapted to be worn by a healthcare provider. The system includes a portal trigger disposed at each door portal of a patient room which activates the reader to record an entrance event when the provider enters the patient room. The system includes a dispenser trigger disposed at each cleaning dispenser having cleanser in or at the entrance of each patient room which activates the reader to record a dispensing event when the provider causes the dispenser to dispense cleanser, the reader having a display which displays a number of dispensing events and a number of entrance events. A method which allows healthcare providers to monitor hand hygiene compliance. A system which allows a person to monitor hand hygiene compliance. A method for allowing a person to monitor hand hygiene compliance.
A61G 12/00 - Accommodation for nursing, e.g. in hospitals, not covered by groups , e.g. trolleys for transport of medicaments or foodPrescription lists
G07C 1/10 - Registering, indicating, or recording the time of events or elapsed time, e.g. time-recorders for work people together with the recording, indicating or registering of other data, e.g. of signs of identity
89.
COMPOSITE PROFILES OF CELL ANTIGENS AND TARGET SIGNAL TRANSDUCTION PROTEINS FOR ANALYSIS AND CLINICAL MANAGEMENT OF HEMATOLOGIC CANCERS
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Methods, systems, and kits useful for determining whether a subject is likely to benefit from therapy with an antibody are provided. In particular aspects, cell-bound complement activation products (CB-CAPs) associated with B lymphocytes may serve as diagnostic biomarkers.
